YS Biopharma Co Ltd (YS)
0.955
0.00 (0.00%)
USD |
NASDAQ |
May 20, 10:00
YS Biopharma Enterprise Value: 130.04M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 130.04M |
| May 16, 2024 | 127.45M |
| May 15, 2024 | 134.88M |
| May 14, 2024 | 130.99M |
| May 13, 2024 | 122.80M |
| May 10, 2024 | 129.30M |
| May 09, 2024 | 127.63M |
| May 08, 2024 | 127.44M |
| May 07, 2024 | 113.48M |
| May 06, 2024 | 110.92M |
| May 03, 2024 | 107.69M |
| May 02, 2024 | 107.71M |
| May 01, 2024 | 108.83M |
| April 30, 2024 | 104.55M |
| April 29, 2024 | 110.69M |
| April 26, 2024 | 113.48M |
| April 25, 2024 | 113.02M |
| April 24, 2024 | 114.41M |
| April 23, 2024 | 114.50M |
| April 22, 2024 | 107.99M |
| April 19, 2024 | 106.54M |
| April 18, 2024 | 118.60M |
| April 17, 2024 | 126.14M |
| April 16, 2024 | 118.49M |
| April 15, 2024 | 121.86M |
| Date | Value |
|---|---|
| April 12, 2024 | 119.06M |
| April 11, 2024 | 119.52M |
| April 10, 2024 | 122.79M |
| April 09, 2024 | 118.13M |
| April 08, 2024 | 120.93M |
| April 05, 2024 | 121.08M |
| April 04, 2024 | 122.65M |
| April 03, 2024 | 117.39M |
| April 02, 2024 | 108.73M |
| April 01, 2024 | 106.50M |
| March 28, 2024 | 106.03M |
| March 27, 2024 | 105.11M |
| March 26, 2024 | 97.66M |
| March 25, 2024 | 99.52M |
| March 22, 2024 | 97.66M |
| March 21, 2024 | 97.33M |
| March 20, 2024 | 97.66M |
| March 19, 2024 | 98.14M |
| March 18, 2024 | 105.67M |
| March 15, 2024 | 106.32M |
| March 14, 2024 | 104.64M |
| March 13, 2024 | 108.07M |
| March 12, 2024 | 101.95M |
| March 11, 2024 | 98.50M |
| March 08, 2024 | 97.47M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
73.47M
Minimum
Feb 02 2024
965.65M
Maximum
Mar 17 2023
140.94M
Average
121.47M
Median
Enterprise Value Benchmarks
| Sinovac Biotech Ltd | -7.011B |
| CASI Pharmaceuticals Inc | 32.35M |
| Zai Lab Ltd | 1.313B |
| Gracell Biotechnologies Inc (DELISTED) | -- |
| Adagene Inc | 24.60M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.51M |
| Revenue (Quarterly) | 13.38M |
| Total Expenses (Quarterly) | 27.21M |
| EPS Diluted (Quarterly) | -0.1565 |
| Gross Profit Margin (Quarterly) | 81.92% |
| Profit Margin (Quarterly) | -108.4% |
| Earnings Yield | -41.68% |
| Normalized Earnings Yield | -30.61 |